To address this health disparity, efforts were made to accelerate the evaluation and introduction of PCV in the WMA population. From April 1997 through August 2000, a phase III trial of a 7-valent PCV (PCV7; Prevnar; Wyeth Vaccines) was conducted among children aged !2 years [4] . In October 2000, routine use of PCV7 began for infants and children aged !5 years. Additionally, in 2002, efforts were made to improve the use of 23-valent pneumococcal polysaccharide vaccine (PS23; Pneumovax; Merck) among elderly WMA persons. This study aimed to evaluate the rate of IPD among WMA persons after the routine use of PCV7 and the expanded use of PS23.
PATIENTS AND METHODS
Study site. The WMA tribe consists of ∼15,000 members [5] with 300 births per year in the population. The Fort Apache Indian Reservation is an area of 2600 square miles in northern Arizona.
Case detection. We conducted active laboratory-and population-based surveillance for isolates of S. pneumoniae from normally sterile sites daily at the Whiteriver Indian Health Service hospital laboratory and weekly at Indian Health Service and non-Indian Health Service health facilities located in surrounding communities. Monthly surveillance audits were conducted to ensure the completeness of data collection. No substantive changes were made in the surveillance system during the study period.
A case of IPD was defined as the isolation of S. pneumoniae from a normally sterile site (e.g. blood, CSF, or pleural fluid) in an American Indian resident of the WMA reservation. Episodes occurring within 7 days after an earlier episode were considered to be relapses and were not counted as separate cases. Cases were included in this analysis if they occurred from 1 January 1991 through 31 December 2006, the period immediately following our previous report on IPD (1983) (1984) (1985) (1986) (1987) (1988) (1989) (1990) [2] . Clinical information was collected by chart review.
We characterized clinical syndromes as described by the treating clinician. We used the Indian Health Service user population statistics to determine the denominator used to calculate rates of IPD; user populations are defined as American Indians (any tribal affiliation) residing on or in the area immediately surrounding the reservation who had had contact with an Indian Health Service facility in the preceding 3 years.
Laboratory methods. Pneumococcal isolates were collected from the clinical laboratory. Serotypes were determined using the Quellung reaction (Statens Serum Institute; Denmark) by the Arctic Investigations Program of the Centers for Disease Control and Prevention (Anchorage, AK). Antimicrobial susceptibility testing was performed by the clinical laboratories of the treating hospitals.
Blood culture practice. From late 1998 through 2004, we monitored blood culture testing practices among febrile children. We used electronic medical records, which included laboratory test results and vital signs, to obtain a monthly estimate of the proportion of children aged !2 years with a temperature of 139.4ЊC who had a blood culture performed.
Vaccine coverage. To describe the PCV7 vaccine coverage on a child-by-child basis, we enumerated all doses administered during the PCV7 efficacy trial period (April 1997-August 2000). From October 2000 through December 2004, we enumerated all PCV7 doses that were administered by the Indian Health Service; we used paper logs and the electronic medical record to estimate PCV7 coverage over time, using denominators calculated from user-population statistics. Adult PS23 vaccine coverage is reported elsewhere [6] .
Statistical methods. Age-specific and overall incidence rates were calculated using Indian Health Service user population statistics. For the years 1991-1992, denominators were estimated using an exponential equation (
) and as- bers, and 8 (3.3%) occurred in members of other tribes living on the WMA reservation. One hundred thirty-two cases (53.7%) occurred in individuals who were male. Cases of IPD were most common in the months from January through March and were least common from July through September. The rate of IPD decreased during the 16-year study period, from 126.2 cases per 100,000 person-years to 86.6 cases per 100,000 person-years ( ) (table 1) . The decrease in the P p .01 overall rate of IPD was attributable to a decreasing rate of IPD among children; the rate of IPD among adults increased from 80.1 cases per 100,000 person-years to 116.4 cases per 100,000 person-years during the 16-year study period ( ). For P p .07 all age groups, the rate of IPD due to PCV7-type pneomococcal strains decreased 72%, from 55.9 cases per 100,000 personyears in the period 1991-1997 to 15. 4 Of the 117 pediatric cases of IPD, 115 (98.3%) had S. pneumoniae isolated from a blood specimen alone, 1 had S. pneumoniae isolated from a synovial fluid specimen, and 1 had S. pneumoniae isolated from both CSF and blood specimens. Most pediatric cases (54%) involved patients who presented with pneumonia; patients in 19% of cases presented with occult bacteremia, and patients in 2.6% of cases presented with meningitis. There were no significant trends in disease syndrome distribution over time. Preexisting conditions were only assessed for cases that occurred from July 2001 through December 2006; of the 16 pediatric cases during this time, 4 involved patients who had an underlying condition (asthma in 2 patients, recurrent pneumonia in 1 patient, and fetal alcohol syndrome and intrauterine growth retardation in 1 patient). Outcomes were not uniformly recorded during the pre-PCV7 baseline period and were therefore not analyzed. During the PCV7 efficacy trial period and the PCV routine-use period, outcomes was no increase in the rate of IPD caused by non-vaccine-type strains (analyzed as a group or as individual serotypes) in the PCV7 routine-use period, compared with the rate observed in the pre-PCV7 baseline period among any pediatric age group (table 2) (table 2) . P p .1 There was no significant change in IPD due to non-PCV7 strains among adults (60.1 cases per 100,000 person-years in the period 1991-1997 and 78.9 cases per 100,000 person-years in the period 2004-2006; ). A broad diversity of pneu-P p .3 mococcal strain serotypes caused IPD in adults during the study period (at least 25 serotypes were identified). Serotypes 7F and 12F were the most common strains identified in the PCV7 routine-use period. Most episodes (77.5%) of IPD in adults were caused by pneumococcal serotypes included in the PS-23 vaccine; there were no significant changes over time in the proportion of isolates that were PS23 serotypes. In 2004-2006, 35% of cases of IPD in adults were caused by serotypes included in the 13-valent PCV. Risk factors, clinical courses, and outcomes among adult WMA persons with IPD are reported elsewhere [6] .
Antimicrobial susceptibility. Antimicrobial susceptibility data was collected for cases of IPD that occurred after July 2001. Of 62 isolates for which penicillin susceptibility testing was performed, 2 (3.2%) were resistant, and 15 (24.2%) had intermediate susceptibility. ). PCV7-serotype isolates were more likely to P p .3 be penicillin-nonsusceptible (66.7%) than were non-PCV7 serotypes (17%) ( ). Sixty-one (100%) of 61 tested iso-P p .005 lates were susceptible to ceftriaxone, 49 (94.2%) of 52 tested isolates were susceptible to erythromycin, and 45 (86.5%) of 52 tested isolates were susceptible to trimethoprim-sulfamethoxazole; there were no significant changes over time with regard to susceptibility to these agents.
Blood culture clinical practice. The proportion of febrile children aged !2 years who had a blood culture collected decreased from 1998 to 2004; 709 blood cultures were collected from children involved in 1504 episodes of febrile illness in this time period. The proportion of febrile children who had a culture collected decreased by a mean of 2.4% per quarter from 1998 to 2000 ( for trend) and by 1% per quarter children aged 19-35 months had received at least 3 doses of PCV7.
DISCUSSION
Since the introduction of PCV7, IPD due to PCV7-type strains has been eliminated among WMA children. Through 31 December 2007, the last case of IPD due to PCV7-type strains among children aged !5 years occurred in 2003, and the child involved died. On the basis of data from the pre-PCV7 baseline period, ∼4 cases of IPD due to PCV7-type stains would have been expected annually among children aged !5 years. Furthermore, unlike observations that were made among rural Alaska Native children [7] , there was no statistically significant increase in the rate of IPD due to non-vaccine-type strains among WMA children, despite the use of PCV7 in the WMA community for 10 years, compared with the use of PCV7 for 6 years in Alaska and high rates of PCV7 coverage in both communities. The differences in experiences with IPD due to non-vaccine-type strains between the 2 communities cannot be ascribed to greater PCV7 use in the Alaska communities, compared with the WMA communities. S. pneumoniae serotype 19A was the strain contributing most to serotype changes in Alaska; some clones of this serotype are known to have significant antimicrobial resistance. Among WMA children, the prevalence of serotype 19A has not changed (1-4 cases per year) (table 3) . Two serotype 19A isolates underwent susceptibility testing; both had intermediate susceptibility to penicillin, 1 was trimethoprim-sulfamethoxazole resistant, and both were susceptible to ceftriaxone and erythromycin. Continued surveillance of IPD among the WMA community is essential to monitor the impact of PCV7 and to detect serotype-specific disease changes.
Reasons for the differences in trend of IPD due to nonvaccine-type strains are not clearly established, but likely include drivers of serotype distribution beyond the use of PCV. Important differences between the 2 communities may include the PCV7 introduction strategy, antibiotic use, antimicrobial resistance of circulating pneumococcal isolates, indoor smoke exposure, or secular trends unrelated to PCV7 introduction; some or all of these differences may contribute to the variation in IPD due to non-vaccine-type pneumococcal strains. These factors should be fully explored to understand the causal or non-causal relationship between PCV introduction and trends in IPD due to non-vaccine-type strains. Overall, most adult pneumococcal disease was due to serotypes covered by the PS23 vaccine, despite a high rate of PS23 use in the population and evidence that the vaccine is effective [6] . The secular trends associated with IPD among adults have to be interpreted in light of trends in risk factor prevalence. Alcoholism, complications resulting from alcoholism, and diabetes were present for individuals involved in 175% of cases [6] ; changes in the prevalence of these risk factors over time will impact the rate of IPD. Antimicrobial resistance among pneumococcal strains remains of concern, because clones with multidrug resistance have emerged and are circulating [12] . In this study, we found penicillin resistance to be uncommon, and its prevalence did not change during the study period.
The analyses presented here are limited by the small size of the WMA population, which has an annual birth cohort of 300 and an adult population of 9000; a single case of IPD results in a measured annual rate of 333 cases per 100,000 personyears among persons aged !1 year and 11 cases per 100,000 person-years among persons aged 118 years. Therefore, surveillance years are grouped, which may mask disease trends. Some isolates were unavailable for serotype testing, particularly during the pre-PCV7 baseline period; there was no systematic reason for isolates being unavailable. The magnitude of the reduction in the rate of IPD during the period 2001-2003 is less than that during the period 2004-2006, likely because PCV7 coverage was still increasing during this interval.
The goals of Healthy People 2010 are to decrease the rate of IPD among children aged !5 years to 46 cases per 100,000 person-years and the rate among adults aged у65 years to 42 cases per 100,000 person-years [13] . The rates of IPD in the period 2004-2006 for these age groups in the WMA population were 120 cases per 100,000 person-years for children aged !5 years and 141 cases per 100,000 person-years for adults aged у65 years, which are much higher than the goal rates of Healthy People 2010 and 5.7-fold and 3.6-fold higher, respectively, than the rates found in the general US population in 2005 (21.2 cases per 100,000 person-years and 39.6 cases per 100,000 person-years, respectively [14] ). Among children aged !2 years, a similar health disparity remains (301.1 cases per 100,000 person-years in the WMA population vs. 35.9 cases per 100,000 person-years in the general US population).
PCV7 has resulted in a dramatic reduction in the burden of IPD among WMA children. There has been no statistically significant increase in IPD due to non-vaccine-type pneumococcal strains after the introduction of PCV7 in any age group. Additional work is needed to effectively reduce the remaining pneumococcal disease health disparity among WMA children and adults. Interventions should focus on pneumococcal vaccines that cover a broader range of disease-causing strains (especially vaccines directed against pneumococcal common proteins) and on efforts to reduce underlying conditions among the adult population.
